Citations

Clear

1792 citation(s) found for "Stephanie".

Diagnostic quality model (DQM): an integrated framework for the assessment of diagnostic quality when using AI/ML
Lennerz, Jochen K. , Salgado, Roberto, Thierauf, Julia , Indave, Iciar, Bard, Adam Z. , Heher, Yael , Baca, Monica E. de , Cree, Ian A. , Bennett, Shannon M. , Özben, Tomris , Ritterhouse, Lauren L. , Bennett, Shannon, Lennerz, Jochen , Salgado, Roberto , Kim, Grace , Sirintrapun, Sahussapont Joseph , Singh, Ankit Kumar , Weissinger, Stephanie Ellen , Bennett, Shannon, Carobene, Anna

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | January 25, 2023 | Volume: 61 | Issue: 4 | Pages: 544-557

10.1515/cclm-2022-1151 | PMID 36696602 Get It

Abstract Background Laboratory medicine has reached the era where promises of artificial intelligence and machine learning (AI/ML) seem palpable. Currently, the primary responsibility for risk-benefit assessment in clinical practice resides with the medical director. Unfortunately, there is no tool or concept that enables diagnostic quality assessment for the various potential AI/ML applications. Specifically, we noted that an operational definition of laboratory diagnostic quality – for the specific purpose of assessing AI/ML improvements – is currently missing. Methods A session at the 3rd Strategic Conference of the European Federation of Laboratory Medicine in 2022 on “ AI in the Laboratory of the Future” prompted an expert roundtable discussion. Here we present a conceptual diagnostic quality framework for the specific purpose of assessing AI/ML implementations. Results The presented framework is termed diagnostic quality model (DQM) and distinguishes AI/ML improvements at the test, procedure, laboratory, or healthcare ecosystem level. The operational definition illustrates the nested relationship among these levels. The model can help to define relevant objectives for implementation and how levels come together to form coherent diagnostics. The affected levels are referred to as scope and we provide a rubric to quantify AI/ML improvements while complying with existing, mandated regulatory standards. We present 4 relevant clinical scenarios including multi-modal diagnostics and compare the model to existing quality management systems. Conclusions A diagnostic quality model is essential to navigate the complexities of clinical AI/ML implementations. The presented diagnostic quality framework can help to specify and communicate the key implications of AI/ML solutions in laboratory diagnostics.
Transplant of organs from donors with positive SARS‐CoV‐2 nucleic acid testing: A report from the organ procurement and transplantation network ad hoc disease transmission advisory committee
Goldman, Jason D. , Pouch, Stephanie M. , Woolley, Ann E. , Booker, Sarah E. , Jett, Courtney , Fox, Cole, Berry, Gerald J. , Dunn, Kelly E., Kittleson, M. , Lee, Dong Heun , Levine, Deborah J. , Marboe, Charles C. , Taimur, Sarah , Te, Helen S. , Fisher, Cynthia E. , Sellers, Marty T. , Levi, Marilyn E. , Klassen, David K. , Danziger‐Isakov, Lara , Lee, Dong Heun , Marklin, Gary , Trindade, Anil J , Michaels, Marian G , La Hoz, Ricardo M , Danziger-Isakov, Lara , Pouch, Stephanie M , Berry, Gerald J , Ho, Chak‐Sum , Razonable, Raymund R. , Anesi, Judith A. , Wood, R. Patrick, Zaffiri, Lorenzo , Hoz, Ricardo M. La

Mayo Clinic

Transplant Infectious Disease | January 25, 2023 | Volume: 25 | Issue: 1 | Pages: No page available

10.1111/tid.14013 | PMID 36694448 Get It

AbstractBackgroundDecisions to transplant organs from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) nucleic acid test‐positive (NAT+) donors must balance risk of donor‐derived transmission events (DDTE) with the scarcity of available organs.MethodsOrgan Procurement and Transplantation Network (OPTN) data were used to compare organ utilization and recipient outcomes between SARS‐CoV‐2 NAT+ and NAT– donors. NAT+ was defined by either a positive upper or lower respiratory tract (LRT) sample within 21 days of procurement. Potential DDTE were adjudicated by OPTN Disease Transmission Advisory Committee.ResultsFrom May 27, 2021 (date of OTPN policy for required LRT testing of lung donors) to January 31, 2022, organs were recovered from 617 NAT+ donors from all OPTN regions and 53 of 57 (93%) organ procurement organizations. NAT+ donors were younger and had higher organ quality scores for kidney and liver. Organ utilization was lower for NAT+ donors compared to NAT– donors. A total of 1241 organs (776 kidneys, 316 livers, 106 hearts, 22 lungs, and 21 other) were transplanted from 514 NAT+ donors compared to 21 946 organs from 8853 NAT– donors. Medical urgency was lower for recipients of NAT+ liver and heart transplants. The median waitlist time was longer for liver recipients of NAT+ donors. The match run sequence number for final acceptor was higher for NAT+ donors for all organ types. Outcomes for hospital length of stay, 30‐day mortality, and 30‐day graft loss were similar for all organ types. No SARS‐CoV‐2 DDTE occurred in this interval.ConclusionsTransplantation of SARS‐CoV‐2 NAT+ donor organs appears safe for short‐term outcomes of death and graft loss and ameliorates the organ shortage. Further study is required to assure comparable longer term outcomes. image
Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group
DuBois, Steven G. , Krailo, Mark , Bender, Julia Glade , Buxton, Allen, Laack, Nadia N. , Randall, R. Lor , Chen, Helen X., Seibel, Nita L. , Boron, Matthew, Terezakis, Stephanie , Hill‐Kayser, Christine E. , Hayes, Andrea, Teot, Lisa A., Womer, Richard B. , Arndt, Carola, Lessnick, Stephen L. , Eutsler, Eric P., Janeway, Katherine A. , Glade-Bender, Julia , Laack, Nadia N Issa , Reid, Joel M , Rakheja, Dinesh , Womer, Richard , Lessnick, Stephen L , Crompton, Brian D , Kolb, E Anders , Reed, Damon R , Janeway, Katherine A , Gorlick, Richard , Seibel, Nita L , Randall, Robert Lor , Hayes, Andrea A., Reid, Joel M. , Rakheja, Dinesh , Crompton, Brian D. , Daldrup-Link, Heike , Reed, Damon R. , Görlick, Richard

Mayo Clinic

Journal of Clinical Oncology | January 20, 2023 | Volume: 41 | Issue: 11 | Pages: 2098-2107

10.1200/jco.22.01815 | PMID 36669140 Get It

PURPOSE Monoclonal antibodies directed against insulin-like growth factor-1 receptor (IGF-1R) have shown activity in patients with relapsed Ewing sarcoma. The primary objective of Children's Oncology Group trial AEWS1221 was to determine if the addition of the IGF-1R monoclonal antibody ganitumab to interval-compressed chemotherapy improves event-free survival (EFS) in patients with newly diagnosed metastatic Ewing sarcoma. METHODS Patients were randomly assigned 1:1 at enrollment to standard arm (interval-compressed vincristine/doxorubicin/cyclophosphamide alternating once every 2 weeks with ifosfamide/etoposide = VDC/IE) or to experimental arm (VDC/IE with ganitumab at cycle starts and as monotherapy once every 3 weeks for 6 months after conventional therapy). A planned sample size of 300 patients was projected to provide 81% power to detect an EFS hazard ratio of 0.67 or smaller for the experimental arm compared with the standard arm with a one-sided α of .025. RESULTS Two hundred ninety-eight eligible patients enrolled (148 in standard arm; 150 in experimental arm). The 3-year EFS estimates were 37.4% (95% CI, 29.3 to 45.5) for the standard arm and 39.1% (95% CI, 31.3 to 46.7) for the experimental arm (stratified EFS-event hazard ratio for experimental arm 1.00; 95% CI, 0.76 to 1.33; 1-sided, P = .50). The 3-year overall survival estimates were 59.5% (95% CI, 50.8 to 67.3) for the standard arm and 56.7% (95% CI, 48.3 to 64.2) for the experimental arm. More cases of pneumonitis after radiation involving thoracic fields and nominally higher rates of febrile neutropenia and ALT elevation were reported on the experimental arm. CONCLUSION Ganitumab added to interval-compressed chemotherapy did not significantly reduce the risk of EFS event in patients with newly diagnosed metastatic Ewing sarcoma, with outcomes similar to prior trials without IGF-1R inhibition or interval compression. The addition of ganitumab may be associated with increased toxicity.
Associations between testing and treatment pathways in lesional temporal or extratemporal epilepsy: A census survey of NAEC center directors
Beatty, Christopher W. , Ahrens, Stephanie M. , Arredondo, Kristen H. , Bagić, Anto , Bai, Shasha , Chapman, Kevin , Ciliberto, Michael A. , Clarke, Dave , Eisner, Mariah , Fountain, Nathan B. , Gavvala, Jay R. , Perry, Μ. Scott , Herman, Susan T. , Ostendorf, Adam P. , Bagić, Anto I , Perry, Michael Scott , Rossi, Kyle C , Wong-Kisiel, Lily C. , Ostendorf, Adam P , Fountain, Nathan , Gavvala, Jay R , Arredondo, Kristen H , Wong‐Kisiel, Lily C.

Mayo Clinic

Epilepsia | January 19, 2023 | Volume: 64 | Issue: 4 | Pages: 821-830

10.1111/epi.17512 | PMID 36654194 Get It

Abstract Objective The evaluation to determine candidacy and treatment for epilepsy surgery in persons with drug‐resistant epilepsy (DRE) is not uniform. Many non‐invasive and invasive tests are available to ascertain an appropriate treatment strategy. This study examines expert response to clinical vignettes of magnetic resonance imaging (MRI)–positive lesional focal cortical dysplasia in both temporal and extratemporal epilepsy to identify associations in evaluations and treatment choice. Methods We analyzed annual report data and a supplemental epilepsy practice survey reported in 2020 from 206 adult and 136 pediatric epilepsy center directors in the United States. Non‐invasive and invasive testing and surgical treatment strategies were compiled for the two scenarios. We used chi‐square tests to compare testing utilization between the two scenarios. Multivariable logistic regression modeling was performed to assess associations between variables. Results The supplemental survey response rate was 100% with 342 responses included in the analyses. Differing testing and treatment approaches were noted between the temporal and extratemporal scenarios such as chronic invasive monitoring selected in 60% of the temporal scenario versus 93% of the extratemporal scenario. Open resection was the most common treatment choice; however, overall treatment choices varied significantly ( p < .001). Associations between non‐invasive testing, invasive testing, and treatment choices were present in both scenarios. For example, in the temporal scenario stereo‐electroencephalography (SEEG) was more commonly associated with fluorodeoxyglucose–positron emission tomography (FDG‐PET) (odds ratio [OR] 1.85; 95% confidence interval [CI] 1.06–3.29; p = .033), magnetoencephalography (MEG) (OR 2.90; 95% CI 1.60–5.28; p = <.001), high density (HD) EEG (OR 2.80; 95% CI 1.27–6.24; p = .011), functional MRI (fMRI) (OR 2.17; 95% CI 1.19–4.10; p = .014), and Wada (OR 2.16; 95% CI 1.28–3.66; p = .004). In the extratemporal scenario, choosing SEEG was associated with increased odds of neuromodulation over open resection (OR 3.13; 95% CI 1.24–7.89; p = .016). Significance In clinical vignettes of temporal and extratemporal lesional DRE, epilepsy center directors displayed varying patterns of non‐invasive testing, invasive testing, and treatment choices. Differences in practice underscore the need for comparative trials for the surgical management of DRE.
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
Dutta, Navnita , Han, Bing , Ciccio, Gina , Cherukuri, Yesesri , Alegria, Victoria R., LaPlant, Betsy, Sher, Taimur , Lanier, Stephanie, Manna, Alak , Heslop, Keisha, Caulfield, Thomas R. , Maldosevic, Emir , Störz, Peter , Asmann, Yan W. , Chanan‐Khan, Asher , Paulus, Aneel , Dutta, Navnita , Han, Bing , LaPlant, Betsy R, Edwards, Brett , Caulfield, Thomas R , Storz, Peter , Asmann, Yan, Chanan-Khan, Asher A., Paulus, Aneel , Ailawadhi, Sikander , Parrondo, Ricardo D , Roy, Vivek , Edwards, Brett, Manochakian, Rami

Mayo Clinic

Cancers | January 12, 2023 | Volume: 15 | Issue: 2 | Pages: 477

10.3390/cancers15020477 | PMID 36672426 Get It

Bcl-2 and Mcl-1 proteins play a role in multiple myeloma (MM) cell survival, for which targeted inhibitors are being developed. AT-101 is an oral drug, which disrupts Bcl-2 and Mcl-1 function, impedes mitochondrial bioenergetic processes and induces apoptosis in MM cells. When combined with lenalidomide and dexamethasone (Rd), AT-101 significantly reduced tumor burden in an in vivo xenograft model of MM. These data provided rationale for a phase I/II study to establish the effective dose of AT-101 in combination with Rd (ARd regimen) in relapsed/refractory MM. A total of 10 patients were enrolled, most with high-risk cytogenetics (80%) and prior stem cell transplant (70%). Three patients were lenalidomide-refractory, 2 were bortezomib-refractory and 3 were daratumumab-refractory. The ARd combination was well tolerated with most common grade 3/4 adverse events being cytopenia’s. The overall response rate was 40% and clinical benefit rate was 90%. The median progression free survival was 14.9 months (95% CI 7.1-NE). Patients responsive to ARd showed a decrease in Bcl-2:Bim or Mcl-1:Noxa protein complexes, increased CD8+ T and NK cells and depletion of T and B-regulatory cells. The ARd regimen demonstrated an acceptable safety profile and promising efficacy in patients with relapsed/refractory MM prompting further investigation in additional patients.
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022
Baehring, Joachim M. , Butowski, Nicholas , Cannon, Donald M. , Chao, Samuel T. , Chheda, Milan G. , Fabiano, Andrew J. , Gigilio, Pierre, Hattangadi‐Gluth, Jona A. , Holdhoff, Matthias , Junck, Larry , Merrell, Ryan , Mrugała, Maciej M. , Nagpal, Seema , Nedzi, Lucien , Nevel, Kathryn , Patel, Toral , Peters, Katherine B. , Rockhill, Jason K., Rusthoven, Chad G. , Shonka, Nicole , Swinnen, Lode J., Weiss, Stephanie E. , Wen, Patrick Y. , Willmarth, Nicole E. , Bergman, Mary Anne, Darlow, Susan, Peters, Katherine B , Nagpal, Seema , Patel, Toral R , Horbinski, Craig , Nabors, Burt , Portnow, Jana , Bhatia, Ankush , Bloch, Orin G. , Brem, Steven , Forsyth, Peter A , Kaley, Thomas , Nghiemphu, Phioanh L. , Parney, Ian F. , Puduvalli, Vinay K. , Wen, Patrick Yung

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 11, 2023 | Volume: 21 | Issue: 1 | Pages: 12-20

10.6004/jnccn.2023.0002 | PMID 36634606 Get It

The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of the following adult CNS cancers: glioma (WHO grade 1, WHO grade 2–3 oligodendroglioma [1p19q codeleted, IDH- mutant], WHO grade 2–4 IDH- mutant astrocytoma, WHO grade 4 glioblastoma), intracranial and spinal ependymomas, medulloblastoma, limited and extensive brain metastases, leptomeningeal metastases, non–AIDS-related primary CNS lymphomas, metastatic spine tumors, meningiomas, and primary spinal cord tumors. The information contained in the algorithms and principles of management sections in the NCCN Guidelines for CNS Cancers are designed to help clinicians navigate through the complex management of patients with CNS tumors. Several important principles guide surgical management and treatment with radiotherapy and systemic therapy for adults with brain tumors. The NCCN CNS Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding molecular profiling of gliomas.
Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia
Murthy, Guru Subramanian Guru , Logan, Brent R. , Bo‐Subait, Stephanie, Beitinjaneh, Amer , Devine, Steven M. , Farhadfar, Nosha , Gowda, Lohith , Hashmi, Shahrukh K. , Nathan, Sunita , Sharma, Akshay , Stefanski, Heather E. , Hsu, Jack W., Panch, Sandhya R. , Shaw, Bronwen E. , Murthy, Guru , Devine, Steven , Hashmi, Shahrukh, Sharma, Akshay , Lazarus, Hillard M. , Yared, Jean A. , Pulsipher, Michael A. , Switzer, Galen E.

Mayo Clinic

American Journal of Hematology | January 6, 2023 | Volume: 98 | Issue: 4 | Pages: 608-619

10.1002/ajh.26834 | PMID 36606713 Get It

Abstract Allogeneic hematopoietic cell transplantation (allo‐HCT) is a potentially curative treatment for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). While many factors influence the outcomes of allo‐HCT, the independent impact of donor–recipient ABO mismatching remains unclear. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified patients aged ≥18 years with AML or ALL who underwent allo‐HCT between 2008 and 2018. Our objectives were to analyze the outcomes of allo‐HCT based on the donor–recipient ABO status (match, minor mismatch, major mismatch, bidirectional mismatch). Among 4946 eligible patients, 2741 patients (55.4%) were ABO matched, 1030 patients (20.8%) had a minor ABO mismatch, 899 patients (18.1%) had a major ABO mismatch, and 276 patients (5.6%) had a bidirectional ABO mismatch. In multivariable analyses, compared to ABO matched allo‐HCT, the presence of a major ABO mismatch was associated with worse overall survival (HR 1.16, 95% CI 1.05–1.29; p = 0.005), inferior platelet engraftment (HR 0.83, 95% CI 0.77–0.90; p < 0.001), and higher primary graft failure (HR 1.60, 95% CI 1.12–2.30, p = 0.01). Relapse, acute graft versus host disease (GVHD) grades III‐IV and chronic GVHD were not significantly associated with ABO status. While donor age was not significantly associated with outcomes, older recipient age was associated with worse survival and non‐relapse mortality. Our study demonstrates that donor–recipient ABO status is independently associated with survival and other post‐transplantation outcomes in acute leukemia. This underscores the importance of considering the ABO status in donor selection algorithms and its impact in acute leukemia.
Prospective Observational Study of Pain Severity and Pain Interference Outcomes Following Percutaneous MRI-guided Laser Ablation or Cryoablation for Focal Painful Peripheral, Soft Tissue Vascular Malformations: 12-month Outcomes
Koepsel, Erica M. Knavel , Powell, Garret M. , Bendel, Emily C. , Howe-Clayton, Desirae L., Favazza, Christopher , Lu, Aiming , Anderson, Katelyn , Tollefson, Megha M. , Woodrum, David A. , Thompson, Scott M. , Bjarnason, Haraldur , Polites, Stephanie F. , Adamo, Daniel A.

Mayo Clinic

Journal of Vascular Anomalies | January 4, 2023 | Volume: 4 | Issue: 1 | Pages: e055

10.1097/jova.0000000000000055 Get It

Background: Percutaneous image-guided thermal ablation has emerged as a treatment option for vascular malformations (VM). However, prospective data on intermediate to long-term effectiveness with uniform follow-up are lacking. Purpose: To prospectively evaluate the 12-month pain severity and pain interference outcomes following percutaneous MRI-guided laser ablation and cryoablation of focal painful, peripheral soft tissue VM. Materials and Methods: Participants undergoing clinically indicated MRI-guided laser ablation and cryoablation for focal painful (worst pain ≥4 out of 10 on Visual Analog Scale), peripheral soft tissue vascular malformations (VM) were enrolled in an IRB-approved prospective, observational study after giving informed consent. Participants completed the Brief Pain Inventory questionnaire prior to ablation and 1, 3, 6, and 12-month postablation. Differences in pain severity and interference outcomes from baseline on a 0 to 10 scale were compared using a paired t-test. Results: Seventeen participants (15 female; mean age 28.3 ± 9.3 years) underwent 24 MRI-guided and monitored ablation sessions including laser (n = 21), cryoablation (n = 2), or both (n = 1) for treatment of painful slow-flow (n = 16) or high-flow (n = 1) VM. Median maximal VM diameter was 5.7 cm (range 1.1 to 31.0 cm). Mean (±SD) preablation worst pain score was 7.9 ± 1.4. There was a significant decrease in worst pain at 1-month postablation (–3.5 ± 2.9; P = .0007) that was sustained at 3 (–3.4 ± 3.2; P = .0007), 6 (–4.2 ± 3.6; P = .0003), and 12 months (–3.6 ± 3.9; P = .002), with similar results for average, current, and least pain scores. There was a significant improvement in pain interference outcomes at 12-month postablation: general activity (P = .018), walking ability (P = .008), work (P = .003), sleep (P = .007), and enjoyment of life (P = .033). Conclusions: These data suggest that MRI-guided and monitored thermal ablation is safe and provides early and sustained significant improvements in pain severity and pain interference outcomes during the first year of follow-up in participants with focal painful peripheral soft tissue VM.
Effect of IL-4 and IL-13 on the chemotaxis of mouse eosinophils (38.2)
Gwinn, William M., Lee, James J. , Constant, Stephanie L., Keegan, Achsah , Heller, Nicola

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 178 | Issue: 1_Supplement | Pages: S23-S23

10.4049/jimmunol.178.supp.38.2 Get It

Abstract Eosinophils are a major pathological component of the inflammatory cell infiltrate found in lungs as a result of allergic disease. They migrate into lungs in response to a variety of chemokines. The development and effector phases of the allergic response are dependent on the actions of interleukin (IL)-4 and IL-13 on a wide variety of cell types. However, how these two cytokines directly affect eosinophil signaling, function and chemotaxis is largely unknown. Using mouse eosinophils purified from IL-5 transgenic mice and a transwell migration assay, eotaxin-1 (30nM) induced eosinophil migration 6–11x over background. IL-4 alone was able to induce eosinophil migration 2x over background. More eosinophils migrated in response to eotaxin when IL-14 or IL-13 was also placed in the bottom chamber. IL-4 appeared to be more potent than IL-13. This effect was dependent upon cytokine concentration. Interestingly, when eosinophils were pretreated with IL-4 for 30 minutes prior to chemotaxis, migration to eotaxin-1 was enhanced 4-fold. However, pretreatment with IL-13 did not enhance chemotaxis to eotaxin-1. These data suggest that IL-4 and IL-13 have direct and rapid effects on the chemotactic function of eosinophils with some differences. We are investigating the mechanisms of these effects, as well as other signaling and functional responses of eosinophils to these cytokines. (AI38985 and HLT32007698)
Perforin expression is required for fatal blood-brain barrier disruption in the Plasmodium berghei ANKA model of cerebral malaria (P3061)
Johnson, Aaron J. , Johnson, Holly L. , Huggins, Matthew, N’Songo, Aurelie, Hanson, Lisa , LaFrance, Stephanie J., Jin, Fang, Pirko, Istvan, Butler, Noah S, Johnson, Aaron J. , Butler, Noah S. , Harty, John T.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 190 | Issue: Supplement_1 | Pages: 187.6-187.6

10.4049/jimmunol.190.supp.187.6 Get It

Abstract The most severe clinical complication of Plasmodium falciparum infection is cerebral malaria (CM). Plasmodium berghei ANKA (PbA) infection of C57BL/6 mice is an established model of CM. Previous work has implied a role for CD8 T cells and perforin expression in fatal stages of PbA infection. We therefore infected C57BL/6 and C57BL/6 Perforin-/- mice with PbA and assessed the CNS for cerebral endothelial cell blood-brain barrier (BBB) disruption using FITC albumin leakage into tissue, confocal microscopy and 3D volumetric T2 and T1 gadolinium enhanced MRI. PbA infected C57BL/6 mice: 1.) had extensive disruption of BBB tight junction proteins Occludin and Claudin 5, 2.) developed severe CNS vascular permeability of FITC albumin and gadolinium leakage, and 3.) became moribund. We also observed increased VEGF cytokine expression coinciding with CNS vascular permeability in these animals. Despite having similar CD8 T cell infiltration into the brain, PbA infected C57BL/6 Perforin-/- mice had intact BBB tight junction, were devoid of CNS vascular permeability, presented with normal brain MRI, and had normal behavioral scores on the rotarod assay. This study is therefore the first to demonstrate the critical importance of perforin expression in promoting BBB tight junction alteration during PbA infection. Therefore, development of therapies to block factors related perforin mediated delivery could have significant benefit to the treatment of CM.